PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 42.4% in September

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 78,900 shares, a decrease of 42.4% from the August 31st total of 136,900 shares. Based on an average daily trading volume, of 2,890,000 shares, the short-interest ratio is currently 0.0 days. Currently, 4.4% of the shares of the company are short sold. Currently, 4.4% of the shares of the company are short sold. Based on an average daily trading volume, of 2,890,000 shares, the short-interest ratio is currently 0.0 days.

PainReform Price Performance

PRFX opened at $1.38 on Friday. The firm has a market cap of $2.77 million, a P/E ratio of -0.01 and a beta of 0.58. PainReform has a 1-year low of $1.25 and a 1-year high of $16.63. The company has a 50 day simple moving average of $1.46 and a two-hundred day simple moving average of $1.76.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a report on Saturday, September 27th. Wall Street Zen raised shares of PainReform from a “strong sell” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.